Search Bar & Filters
Found 20 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness and safety of enicepatide, a dual GLP-1 and GIP receptor agonist, for weight management in adults with obesity or overweight who also have Type 2 diabetes mellitus T2DM. This phase III clinical trial compares multiple doses of enicepatide with a placebo to understand its impact on body weight and diabetes control. Participants will receive once-weekly injections of enicepatide or a placebo using an integrated drug-device combination product. The study has several dosing regimens for enicepatide and includes a placebo group for comparison. Treatment lasts up to 72 weeks, during which participants will receive their assigned injections regularly. Throughout the study, participants will be closely monitored with various assessments including body weight, hemoglobin A1c levels, waist circumference, fasting glucose and insulin levels, cholesterol levels, blood pressure, and quality of life measures. Safety evaluations will also be conducted to track adverse events. The study duration extends through week 72, with multiple outcome measures evaluated from baseline to the end of treatment.
Actively Recruiting
Researchers are evaluating whether the drugs retatrutide and tirzepatide can prevent major adverse liver outcomes MALO in adults with metabolic dysfunction-associated steatotic liver disease MASLD, a condition that puts them at higher risk for severe liver problems. This Phase 3 trial is designed as a randomized, controlled study involving about 4,500 adults with MASLD identified through non-invasive tests indicating increased risk for liver complications. Participants will be randomly assigned to receive either retatrutide, tirzepatide, or a placebo, all given by subcutaneous injection. The study will last approximately 224 weeks, with up to 25 to 30 clinic visits to monitor health, conduct procedures, and assess liver function and disease progression. After completing the main study, eligible participants may join an optional 2-year extension where all receive either retatrutide or tirzepatide, regardless of initial assignment. Throughout the trial, participants will undergo assessments including liver fat content measurements, liver stiffness tests, liver fibrosis scores, and blood tests for liver enzymes and body weight changes. The primary outcome is the time until the first major adverse liver event occurs. Safety and disease progression will be closely monitored during and after treatment through regular clinic visits and evaluations.
Actively Recruiting
Researchers are conducting a Phase 1, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of VK2735 in adults who are obese with a BMI of 30 kgm2 or higher and do not have other medical conditions. The study aims to understand how VK2735 behaves in the body and its safety profile in this specific group. The study involves approximately 270 adult participants divided into two parts, Part A and Part B. Participants in Part A are randomized equally into 12 treatment groups to receive one of 11 VK2735 dose regimens or a matching placebo, while Part B includes 6 treatment groups with four VK2735 dose regimens or placebo. Each part consists of two treatment periods lasting 21 weeks and 12 weeks, during which participants may receive different dosing schedules and routes of VK2735 administration, including subcutaneous injections or oral doses weekly, every other week, or monthly. Participants will be closely monitored throughout the study for safety and tolerability over 33 weeks. Researchers will also evaluate how the drug is processed in the body over 38 weeks. Assessments include physical exams, laboratory tests, and adherence to contraceptive guidelines. The study lasts until July 2027, and participants will have regular visits to track their health and responses to the drug or placebo during the treatment periods.
Actively Recruiting
Researchers are evaluating VK3019, an amylin and calcitonin receptor agonist, in overweight and obese adults without other health conditions. This Phase 1 randomized, double-blind, placebo-controlled study aims to assess the safety, tolerability, pharmacodynamics, and pharmacokinetics of single doses of VK3019 in participants aged 18 to 60 years with a body mass index between 27 and 40 kgm2. About 56 participants will be divided into seven cohorts, each receiving a single subcutaneous dose of VK3019 or a matching placebo. Each cohort begins with two sentinel participants dosed on the same day, one receiving VK3019 and one placebo. If no safety concerns arise within 48 hours, the remaining participants in the cohort receive the same dose. Safety Review Committee meetings guide dose escalation decisions throughout the study. Participants will be monitored for safety and drug levels for 36 days following dosing. Assessments include physical exams, laboratory tests, and safety reviews to evaluate any adverse effects. The study evaluates the pharmacokinetic profile and tolerability of VK3019 while ensuring participant safety during the observation period.
Actively Recruiting
Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the long-term effects of aleniglipron, an oral drug, in adults living with obesity or overweight and type 2 diabetes mellitus T2DM. This randomized, double-blind, placebo-controlled phase 3 study aims to assess the efficacy, safety, and tolerability of multiple doses of aleniglipron for chronic weight management in this population. Participants will be randomly assigned to receive either oral aleniglipron or a placebo once daily. The treatment period lasts for 76 weeks, during which participants will take the assigned medication regularly. The study includes several experimental arms receiving aleniglipron and one placebo arm to compare outcomes. During the study, participants will have assessments at baseline and week 76 to measure changes in body weight, waist circumference, HbA1c levels, blood pressure, triglycerides, and cholesterol. Researchers will track the percentage of participants achieving significant weight loss and HbA1c targets. Safety and tolerability will be monitored throughout the treatment period, with the total participation lasting approximately 76 weeks.
Actively Recruiting
Researchers are evaluating the efficacy and safety of orforglipron in adults with overweight who are at risk of developing obesity-related complications such as type 2 diabetes, hypertension, and dyslipidemia, or progressing to class 1 obesity. The study is a phase 3, randomized, double-blind, placebo-controlled trial that aims to understand whether this oral medication can reduce these risks over a two-year period. Participants will be randomly assigned to one of three groups receiving orforglipron orally throughout, orforglipron followed by placebo, or placebo followed by orforglipron. The study involves daily oral administration of these medications. The trial includes a long-term treatment period lasting up to 104 weeks about two years, during which participants are monitored for weight changes and the onset of obesity-related health issues. Throughout the study, participants will undergo regular assessments including measurements of body weight, waist circumference, blood pressure, blood markers like glycated hemoglobin and triglycerides, and quality of life questionnaires. Researchers will also monitor the time to onset of obesity-related complications and pharmacokinetics of orforglipron at specified intervals. Safety and effectiveness will be tracked continuously, with the primary outcome being the time until the development of obesity-related complications or progression to class 1 obesity.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the safety and immune response of a new multivalent pneumococcal conjugate vaccine called PG4 in adults aged 18 to 49 years. The study compares three different production lots of the PG4 vaccine to each other and to an existing 20-valent pneumococcal conjugate vaccine 20vPnC to confirm consistent vaccine performance and safety. Participants are randomly assigned to one of four groups three groups receive one of the three different lots of the PG4 vaccine, and the fourth group receives the 20vPnC vaccine. Each participant receives a single injection of their assigned vaccine in the arm. The study uses a randomized, double-blind design with groups allocated in a 2221 ratio to ensure balanced comparison. During the approximately six-month study participation, blood samples are collected to measure immune responses and monitor safety. Researchers assess local and systemic reactions within one week after vaccination, adverse events up to one month, and serious adverse events up to six months. They also analyze specific antibody levels and immune activity to evaluate how the vaccines stimulate the bodys defenses against pneumococcal disease.
Actively Recruiting
Researchers are evaluating the safety and tolerability of single and multiple intravenous doses of GIGA-2339 in adults with chronic Hepatitis B Virus HBV infection. This Phase 1 randomized, double-blind, placebo-controlled study aims to understand how GIGA-2339 behaves in the body and monitor any side effects in participants with stable HBV infection. Participants will receive either a single ascending dose or multiple ascending doses of GIGA-2339 or placebo through intravenous infusion. In Part 1, they get a single infusion on Day 1, and in Part 2, they receive multiple infusions every 4 weeks at doses determined from Part 1. The study compares these treatments to placebo to evaluate safety and pharmacokinetics. During the study, participants undergo regular blood tests to measure drug levels and monitor safety up to Day 105 for the single dose and Day 245 for multiple doses. Researchers record any adverse events and serious side effects. The study lasts until November 2028, with ongoing assessments of participants responses and tolerability throughout the dosing and follow-up periods.
Actively Recruiting
Researchers are evaluating the effectiveness, pharmacodynamics, and safety of ALN-AGT01 RVR in adults with mild to moderate hypertension who have been pretreated with zilebesiran. The study is a phase 2, randomized, double-blind, placebo-controlled trial designed to assess how ALN-AGT01 RVR works following a single dose of zilebesiran. The study is conducted in two parts. Part A involves a single dose, dose-ranging phase for adults with mild to moderate hypertension, while Part B involves a single dose phase in a similar population. Participants receive a single dose of zilebesiran followed by either a single dose of ALN-AGT01 RVR or a placebo, both administered subcutaneously. Participants will be monitored for blood pressure changes, serum angiotensinogen levels, and adverse events over several days and months. The primary outcomes include the percentage recovery from baseline in serum angiotensinogen and mean seated office systolic blood pressure at specified days. Safety is assessed by tracking adverse events for up to 10 months, and participant involvement includes visits for dosing and follow-up assessments throughout the study duration.
1-10 of 20
1